Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma

Journal of Nuclear Medicine

Volumn 50, Issue 9, 2009, Pages 1518-1524

  Buckley, Susan E ^a   Chittenden, Sarah J ^a   Saran, Frank H ^a   Meller, Simon T ^a   Flux, Glenn D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

131I MIBG therapy; Dosimetry; Neuroblastoma; Treatment planning

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; TOPOTECAN; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; DOSIMETRY; HUMAN; LEUKOPENIA; NEUROBLASTOMA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT PLANNING;

3-IODOBENZYLGUANIDINE; ADOLESCENT; BODY BURDEN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEUROBLASTOMA; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; WHOLE-BODY COUNTING; YOUNG ADULT;

EID: 69449099787     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.064469     Document Type: Article

References (33)

1. Gedik GK, Hoefnagel CA, Bais E, Valdes Olmos RA. 131-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35:725-733.
2. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol. 2002;20:2142-2149.
3. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
4. Council of the European Union. Council directive 97/43/EURATOM on health protection of individuals against the dangers of ionizing radiation in relation to medical exposure. Off J Eur Comm. 1997;180:0022-0027.
5. Moyes JSE, Babich JW, Carter R, Meller ST. Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: correlation with tumour histopathology. J Nucl Med. 1989;30:474-480. (Pubitemid 19096592)
6. Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of I-131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med. 1991;18:308-316.
7. 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm. 2005;20:195-199.
8. DeNardo SL, Williams LE, Leigh BR, Wahl RL. Choosing an optimal radioimmunotherapy dose for clinical response. Cancer. 2002;15(4 suppl):1275-1286. (Pubitemid 34150890)
9. Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978-1997): report from the automated childhood cancer information system project. Eur J Cancer. 2006;42:2081-2091.
10. Mairs RJ, Gaze MN, Barrett A. The uptake and retention of metaiodobenzylguanidine by the neuroblastoma cell line NB1-G. Br J Cancer. 1991;64:293-295.
11. Garaventa A, Bellagamba O, Lo Piccolo MS, et al. I-131- metaiodobenzylguanidine (I-131-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer. 1999;81:1378-1384.
12. 131I- metaiodobenzylguanidine in diagnosis and treatment of neuroblastoma. Bull Cancer. 1988;75:107-111.
13. Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of I-131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol. 1992;10:1889-1896.
14. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with I-131-MIBG. J Nucl Med. 2001;42:1713-1721. (Pubitemid 33131334)
15. Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H. Patient dosimetry for I-131-MIBG therapy for neuroendocrine tumours based on I-123-MIBG scans. Eur J Nucl Med Mol Imaging. 2002;29:1581-1587. (Pubitemid 35435727)
16. 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm. 2007;22:105-112.
17. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39(8 suppl):14S-20S. (Pubitemid 28371371)
18. 131I-meta-iodobenzylguanidine. Eur J Nucl Med. 1988;14:337-340.
19. Chittenden SJ, Pratt BE, Pomeroy K, et al. Optimization of equipment and methodology for whole-body activity retention measurements in children undergoing targeted radionuclide therapy. Cancer Biother Radiopharm. 2007;22:243-249. (Pubitemid 46988425)
20. Flux GD, Guy MJ, Beddows R, Pryor M, Flower MA. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol. 2002;47:3211-3223. (Pubitemid 35049307)
21. Cristy M, Eckerman K. Specific Absorbed Fractions of Energy at Various Ages from Internal Photon Sources. ORNL/TM-8381 V1-V7. Oak Ridge, TN: Oak Ridge National Laboratory; 1987.
22. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181. (Pubitemid 36962641)
23. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694. (Pubitemid 23115673)
24. Buffa FM, Flux GD, Guy MJ, et al. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for Re-186-HEDP treatment of skeletal metastases from prostate cancer. Eur J Nucl Med Mol Imaging. 2003;30:1114-1124.
25. Flux GD, Guy MJ, Papavasileiou P, et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm. 2003;18:81-87. (Pubitemid 36307469)
26. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys. 1988;15:1299-1305. (Pubitemid 19015470)
27. Jen YM, Lin YS, Su WF, et al. Dose escalation using twice-daily radiotherapy for nasopharyngeal carcinoma: does heavier dosing result in a happier ending? Int J Radiat Oncol Biol Phys. 2002;54:14-22.
28. Firat S, Murray K, Erickson B. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int J Radiat Oncol Biol Phys. 2003;57:201-207. (Pubitemid 36959757)
29. Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000;47:1191-1200. (Pubitemid 30421171)
30. Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101-108. (Pubitemid 28211308)
31. Mastrangelo R, Tornesello A, Lasorella A, et al. Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neurooncol. 1997;31:153-158. (Pubitemid 27077722)
32. McCluskey AG, Boyd M, Ross SC, et al. 131I-meta-iodobenzylguanidine and topotecan combination treatment of tumours expressing the noradrenaline transporter. Clin Cancer Res. 2005;11:7929-7937. (Pubitemid 41611640)
33. Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm. 2003;18:89-97.